| (Values in U.S. Thousands) | Dec, 2016 | Dec, 2015 | Dec, 2014 | Dec, 2013 | Dec, 2012 |
| Sales | 2,510 | 1,440 | 1,810 | 2,430 | 2,240 |
| Sales Growth | +74.31% | -20.44% | -25.51% | +8.48% | -21.68% |
| Net Income | -7,410 | -7,900 | -6,340 | -7,060 | -5,120 |
| Net Income Growth | +6.20% | -24.61% | +10.20% | -37.89% | -1.79% |
Interleukin Genetics (ILIU)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Interleukin Genetics is a biotechnology company focused on developing personalized health products, particularly in regard to modulating the role of inflammation in chronic disease. The company is developing or plans to develop risk assessment tests, pharmacogenetic tests, and nutritional and therapeutic products keyed to genetic variations in people. Interleukin's current programs focus on cardiovascular disease, osteoporosis, periodontal disease, and weight management.
Fiscal Year End Date: 12/31